Disappointing results for moxifloxacin in the treatment of acute bacterial rhinosinusitis
An evaluation of the safety and efficacy of moxifloxacin for the treatment of acute bacterial rhinosinusitis (ABRS) has been carried out by staff in the Department of Otolaryngology-Head and Neck Surgery, University of Rochester Medical School, Rochester, New York. The study was a prospective, multicenter, randomized double-blind phase III trial in 118 patients with SBRS. Unfortunately, a 5-day treatment with moxifloxacin was not superior to the placebo in terms of the primary end point (clinical response). However, those on moxifloxacin exhibited greater improvements in health outcomes and required fewer concomitant medicines.
Laryngoscope. 2010 May; 120(5):1057-62.
Source : http://www.ncbi.nlm.nih.gov/pubmed/20422704?dopt=Abstract